Clinical Research
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling pathway is frequently activated in breast cancer and can promote tumor growth, progression, and resistance to anticancer therapies such as endocrine therapy (ET).
David E. Gerber, MD, Martin Reck, Matthew D. Hellmann, Luis Paz-Ares, Hossein Borghaei, Julie Brahmer, Kenneth J. O'Byrne, Prabhu Bhagavatheeswaran, Faith Nathan, Suresh S. Ramalingam
CheckMate 227 (NCT02477826) is a large phase 3 study of first-line nivolumab or nivolumab-based regimens vs chemotherapy in advanced NSCLC.
Multiple tyrosine kinase inhibitors (TKIs) that target the BCR-ABL1 ATP-binding site are available for treating chronic myeloid leukemia (CML).
The COMBI-AD trial demonstrated that adjuvant treatment with dabrafenib + trametinib (D+T) in patients (pts) with resected stage III BRAF-mutant melanoma significantly reduced the risk of melanoma recurrence vs placebo (PBO).
Dirk Schadendorf, MD, Axel Hauschild, MD, Mario Santinami, MD, Victoria Atkinson, MD, Mario Mandalà, MD, Vanna Chiarion Sileni, MD, James Larkin, MD, PhD, Marta Nyakas, MD, Caroline Dutriaux, MD, Andrew Haydon, MD, PhD, Laurent Mortier, MD, Caroline Robert, MD, PhD, Jacob Schachter, MD, Ran Ji, Paola Aimone, Stephanie Manson, Richard Kefford, MD, PhD, Reinhard Dummer, MD, John M. Kirkwood, MD, Georgina V. Long, MD, PhD
Adjuvant treatment (tx) of resected stage III BRAF-mutant melanoma with dabrafenib + trametinib (D+T) significantly reduced the risk of recurrence vs placebo (PBO).
Karwyn S. Gustafson, RN, MSN, Francisco J. Esteva, MD, PhD, Peter Jiang, MD, J. Thaddeus Beck, MD, Dennis J. Slamon, MD, PhD
Ribociclib combined with an aromatase inhibitor has been shown to significantly prolong progression-free survival (PFS) in premenopausal and postmenopausal women with hormone receptor–positive, human epidermal growth factor receptor 2–negative (HR+/HER2−) advanced breast cancer (ABC) who had not been treated previously for ABC.
Endocrine therapy (ET) is an established treatment for premenopausal women with hormone receptor–positive (HR+)/human epidermal growth factor receptor 2–negative (HER2−) advanced breast cancer (ABC). MONALEESA-7 (NCT02278120) was the first phase 3 randomized trial of a cyclin-dependent kinases 4 and 6 inhibitor (ribociclib) + ET in premenopausal women with HR+/HER2− ABC without prior ET for ABC.
Andrea Ardizzoni, Anna F. Farago, Akin Atmaca, Emiliano Calvo, Fiona Taylor, Bryan Bennett, Giovanni Selvaggi, Anne Pieters, John R. Penrod, Yong Yuan, D. Ross Camidge
CheckMate 032 (NCT01928394) is an open-label, phase 1/2 trial evaluating the efficacy and safety of nivolumab monotherapy and nivolumab plus ipilimumab in patients with advanced or metastatic solid tumors. In this study, nivolumab alone or in combination with ipilimumab showed durable responses, encouraging survival, and manageable safety in patients with small cell lung cancer (SCLC) that progressed after ≥1 previous platinum-containing regimens.
Megan Andersen, NP, Tolu Adewuya, MMedSci, PhD, CCRC, Jianling Li, MS, Zeena Salman, BS, Israel Arango-Hisijara, MD, Leonard T. Heffner, MD, Jeffrey V. Matous, MD
Ibrutinib is an inhibitor of Bruton’s tyrosine kinase (BTK) that has demonstrated activity in relapsed Waldenström’s macroglobulinemia (WM). Single-agent ibrutinib is approved in the United States and Europe for WM.
Julie Prettyman, RN, BSN, CCRC, John A. McLane, PhD, Stuart N. Atkinson, MB, ChB, Allison Tyler, RN, BSN, OCN, CCRP, Deborah M. Boldt-Houle, PhD
In prostate cancer therapy, achieving and maintaining effective testosterone (T) suppression to the level attained with surgical castration is the cornerstone of androgen deprivation therapy (ADT).
© 2009- DBA AONN+ Academy of Oncology Nurse & Patient Navigators® PO Box 563, Cranbury, NJ 08512